Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion

Core Viewpoint - The company is focused on developing drugs that specifically target a molecular driver of cancers [1] Group 1 - The company is engaged in the research and development of innovative cancer therapies [1] - The approach taken by the company aims to address the underlying molecular mechanisms of cancer [1] - The potential impact of these drugs could significantly alter treatment paradigms in oncology [1]